RAGE Biotech
PrivateLast Round
Series A
Nov 13, 2025
Total Funding Raised
$24.17M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
RAGE Biotech operates in Healthcare & Life Sciences and is based in Melbourne. Its latest recorded funding round was a Series A round in November 2025.
RAGE Biotech is a biotechnology company developing novel therapeutics targeting the Receptor for Advanced Glycation End-products (RAGE) for patients with difficult-to-treat inflammatory disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
RAGE Biotech Comparables
Compare RAGE Biotech with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cantex Pharmaceuticals | 77% | |
| Arrowhead Pharmaceuticals | 76% | |
| Ethris | 72% |
For institutional investors. Book with your work email.
RAGE Biotech Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Nov 13, 2025 | ||||
| Grant | Sep 4, 2025 | ||||
| Grant | Sep 4, 2024 | ||||
| Accelerator | Apr 18, 2024 | ||||
| Grant | Dec 21, 2022 | ||||
Grant | Jul 19, 2022 |
For institutional investors. Book with your work email.
RAGE Biotech Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| IP Group | Seed |
| CUREator | Grant |
| Hostplus Superannuation Fund | Series A |
| IP Group Australia | Series A |
| mRNA Victoria | Grant |
| Monash Investment Holdings | Seed, Series A |
| Jumar Bioincubator | Accelerator |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 13, 2025
$21M round completed.
- Sep 4, 2025
$75K grant received from CUREator.
For institutional investors. Book with your work email.
RAGE Biotech Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about RAGE Biotech's valuation, stock price, and market status.
Is RAGE Biotech a public or private company?
RAGE Biotech is a private company.
What is the current stock price of RAGE Biotech?
RAGE Biotech is a private company, so its shares have no public market price. Caplight tracks RAGE Biotech's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is RAGE Biotech worth (valuation)?
Valuation information for RAGE Biotech is not publicly available.
Can I buy RAGE Biotech stock?
RAGE Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was RAGE Biotech's last funding round?
RAGE Biotech's most recent funding round was Series A on November 13, 2025.
Who are the main investors in RAGE Biotech?
Key investors in RAGE Biotech include IP Group, Hostplus Superannuation Fund, IP Group Australia.
Will RAGE Biotech IPO soon?
No public IPO plans have been announced for RAGE Biotech.
How can I track RAGE Biotech secondary market activity?
Caplight tracks bids, offers, and trades in RAGE Biotech's shares on secondary markets.